Amplia Therapeutics Ltd (ATX) - Total Assets
Based on the latest financial reports, Amplia Therapeutics Ltd (ATX) holds total assets worth AU$44.54 Million AUD (≈ $31.52 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ATX net assets for net asset value and shareholders' equity analysis.
Amplia Therapeutics Ltd - Total Assets Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Amplia Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Amplia Therapeutics Ltd's total assets of AU$44.54 Million consist of 65.1% current assets and 34.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$10.86 Million | 47.4% |
| Accounts Receivable | AU$3.77 Million | 16.4% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$17.36K | 0.1% |
| Intangible Assets | AU$7.94 Million | 34.6% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Amplia Therapeutics Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amplia Therapeutics Ltd's current assets represent 65.1% of total assets in 2025, an increase from 14.1% in 2010.
- Cash Position: Cash and equivalents constituted 47.4% of total assets in 2025, up from 13.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, a decrease from 82.0% in 2010.
- Asset Diversification: The largest asset category is cash and equivalents at 47.4% of total assets.
Amplia Therapeutics Ltd Competitors by Total Assets
Key competitors of Amplia Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Amplia Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.17 | 4.35 | 7.60 |
| Quick Ratio | 28.17 | 4.35 | 7.60 |
| Cash Ratio | 22.76 | 3.22 | 6.12 |
| Working Capital | AU$34.81 Million | AU$4.74 Million | AU$4.06 Million |
Amplia Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Amplia Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 2.22 |
| Asset Growth Rate (YoY) | 54.5% |
| Total Assets | AU$22.94 Million |
| Market Capitalization | $50.82 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Amplia Therapeutics Ltd's assets at a significant premium (2.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Amplia Therapeutics Ltd's assets grew by 54.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Amplia Therapeutics Ltd (2010–2025)
The table below shows the annual total assets of Amplia Therapeutics Ltd from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | AU$22.94 Million ≈ $16.23 Million |
+54.51% |
| 2024-03-31 | AU$14.85 Million ≈ $10.50 Million |
-20.55% |
| 2023-03-31 | AU$18.68 Million ≈ $13.22 Million |
-23.69% |
| 2022-03-31 | AU$24.48 Million ≈ $17.32 Million |
+125.05% |
| 2021-03-31 | AU$10.88 Million ≈ $7.70 Million |
+19.34% |
| 2020-03-31 | AU$9.12 Million ≈ $6.45 Million |
-0.82% |
| 2019-03-31 | AU$9.19 Million ≈ $6.50 Million |
+247.67% |
| 2018-03-31 | AU$2.64 Million ≈ $1.87 Million |
-64.92% |
| 2017-03-31 | AU$7.54 Million ≈ $5.33 Million |
+49.70% |
| 2016-03-31 | AU$5.03 Million ≈ $3.56 Million |
-5.35% |
| 2015-03-31 | AU$5.32 Million ≈ $3.76 Million |
-47.73% |
| 2014-03-31 | AU$10.18 Million ≈ $7.20 Million |
-10.94% |
| 2013-03-31 | AU$11.43 Million ≈ $8.08 Million |
+98.92% |
| 2012-03-31 | AU$5.74 Million ≈ $4.06 Million |
-26.86% |
| 2011-03-31 | AU$7.85 Million ≈ $5.56 Million |
-4.31% |
| 2010-03-31 | AU$8.21 Million ≈ $5.81 Million |
-- |
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more